Abstract
Anti-HIV combination therapies in a single formulation currently target only HIV-1 reverse transcriptase via two different mechanisms of action by associating a nucleoside and a non-nucleoside reverse transcriptase inhibitor. These combination therapies are therefore referred to as multi-class combination products. The elvitegravir Quad pill (Gilead Sciences), when approved by the Food and Drug Administration for the treatment of HIV/AIDS, will become the first once-daily dual-target anti-HIV tablet. This "4 in 1" tablet targets HIV-1 integrase by elvitegravir boosted by the pharmaco-enhancer cobicistat and HIV-1 reverse transcriptase by the two nucleoside reverse transcriptase inhibitors emtricitabine + tenofovir disoproxil fumarate. A second pill referred to as the 572-Trii pill (Shionogi-ViiV Healthcare, LLC), also based on the dual inhibition of integrase and reverse transcriptase, is currently in late-phase clinical trials. The availability of these novel once-daily anti-HIV tablets will improve treatment adherence and offer new perspective for patient failing existing antiviral regimens.
References
Apr 17, 2007·Lancet·Beatriz GrinsztejnUNKNOWN Protocol 005 Team
Aug 16, 2008·Biochemistry·Jessica MarinelloYves Pommier
Aug 4, 2009·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Martin MarkowitzUNKNOWN Protocol 004 Part II Study Team
Feb 2, 2010·Nature·Stephen HarePeter Cherepanov
Mar 26, 2010·Biochemistry·Mathieu MétifiotYves Pommier
Mar 18, 2011·AIDS·Calvin CohenBrian P Kearney
Apr 21, 2011·AIDS·Mathieu MétifiotYves Pommier
May 24, 2011·HIV Medicine·Jk RockstrohB-Yt Nguyen
Jul 2, 2011·Molecular Pharmacology·Stephen HarePeter Cherepanov
Sep 22, 2011·The Lancet Infectious Diseases·Joseph J EronUNKNOWN QDMRK Investigators
Oct 22, 2011·The Lancet Infectious Diseases·Jean-Michel MolinaUNKNOWN Study 145 Team
Oct 25, 2011·The Lancet Infectious Diseases·Jan van LunzenSherene Min
Nov 1, 2011·Antimicrobial Agents and Chemotherapy·Barry C JohnsonStephen H Hughes
Dec 17, 2011·Nature Reviews. Drug Discovery·Yves Pommier, Christophe Marchand
Feb 15, 2012·The Pediatric Infectious Disease Journal·Verónica BrizMa Ángeles Muñoz-Fernández
Citations
Dec 13, 2012·Journal of Chemical Information and Modeling·Weiwei XueXiaojun Yao
Aug 8, 2013·Journal of Medicinal Chemistry·Jens-Uwe Peters
Aug 14, 2013·Retrovirology·Soundasse MunirOlivier Delelis
Mar 7, 2014·PloS One·Weiwei XueXiaojun Yao
Jul 23, 2013·Viruses·Md Alamgir HossainCha-Gyun Shin
Aug 2, 2012·Expert Opinion on Pharmacotherapy·Rik Schrijvers, Zeger Debyser
Oct 25, 2014·Viruses·Pinar Iyidogan, Karen S Anderson
Dec 18, 2012·Current Opinion in Infectious Diseases·Peter K QuashieMark A Wainberg
May 7, 2013·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Ole J BjerrumHarrie C M Boonen
Apr 23, 2016·European Journal of Medicinal Chemistry·Muriel BillambozPhilippe Cotelle
Jul 3, 2016·Nucleic Acids Research·Mathieu MétifiotYves Pommier
Nov 12, 2013·Journal of Chemical Information and Modeling·Qi ChenDongqing Wei
Jun 6, 2014·ACS Medicinal Chemistry Letters·Muriel BillambozPhilippe Cotelle
May 6, 2014·Journal of Medicinal Chemistry·Virginie SuchaudPhilippe Cotelle
Oct 15, 2014·International Journal of STD & AIDS·Asma Khatri, Marion J Skalweit
Jan 27, 2017·Frontiers in Microbiology·Eloïse ThierryOlivier Delelis
Dec 12, 2013·Journal of Acquired Immune Deficiency Syndromes : JAIDS·David B HannaRobert C Kaplan
Jul 3, 2021·Microorganisms·Maria IsaguliantsAnastasia Latanova
Jun 12, 2014·Journal of Medicinal Chemistry·Major GooyitKim D Janda